BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PathoLase, Inc.: Breakthrough PinPointe FootLaser Treatment from PathoLase Receives CE Mark


5/21/2009 7:31:28 AM

Bookmark and Share

CHICO, Calif.--(BUSINESS WIRE)--PinPointe™ FootLaser™ today announced that it has received CE Mark approval for its new treatment for toenail fungus (Onychomycosis), certifying that it has met EU consumer and health safety standards and can be offered by certified health care providers throughout Europe.

PinPointe FootLaser uses a patented laser technology to treat toenail fungus (Onychomycosis), an infection that afflicts an estimated 900 million people around the world. With PinPointe FootLaser, patients are treated quickly and effectively with no oral or systemic drugs and no anesthesia. PinPointe’s laser light passes through the toenail without causing damage to the nail or surrounding skin. The procedure allows the new nail to grow in healthy and clear. Unlike competing medication-driven treatments for toenail fungus, PinPointe FootLaser presents minimal risk of side effects.

By offering a simple, non-invasive solution for patients suffering from toenail fungus, PinPointe FootLaser offers licensed healthcare providers an excellent opportunity for building their practice and providing a valuable service to their patients. PinPointe FootLaser is an emerging leader in the medical technology industry.

About PathoLase

Founded in 2004, PathoLase, Inc. is a privately held emerging medical technology company with headquarters in Northern California. PathoLase has assembled a world-class group of top scientists, academic thought leaders and leading practitioners from around the U.S. and Canada to develop and bring to market a new generation of laser technology solutions that address a series of medical issues, from toenail fungus and periodontal disease to more serious life threatening problems, such as blood borne and respiratory infections. For more information please visit http://www.pinpointefootlaser.com/eu

Contact:

Media: DBA Public Relations Matthew Calderone U.S. Phone: (212) 388-1400 ext. 29 mcalderone@dba-pr.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES